Glenn A. Phillips, PhD, serves as the Senior Director Health Economics and Outcomes Research (HEOR) at argenx, a global immunology company. A seasoned HEOR professional, Glenn has worked in pharma/biotech HEOR for 17 years in roles in both large pharmaceutical companies and small biotechs, including Biogen, Lilly, Akcea and Rhythm. Most recently, Glenn participated in ICER’s public review of treatments for myasthenia gravis (MG), where he highlighted data supporting the value of efgartigimod, an investigational therapy being studied in patients with generalized MG. He is a strong advocate for the patient perspective to be a key component of value assessments, especially in areas of significant unmet need. As the global head of HEOR at argenx Glenn is using his vast expertise in the field to help shape this function at argenx. Glenn earned a PhD in clinical psychology with an emphasis in research design and statistics from the University of Memphis. He has published more than 40 scientific articles on disease burden and associated economic costs.
1:45 PM - 2:45 PM (PDT)
Wednesday, June 15
The value equation can be very different for patients with various conditions in different…